Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 16/20 | 0.37 |
| ▸ | SLC6A4 known ✓ | P31645 | 16/20 | 0.37 |
| ▸ | SLC6A3 known ✓ | Q01959 | 13/20 | 0.37 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.35 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.35 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.35 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.35 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.35 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250056 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL9054370 | 0.83 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3KCNH2MLNR | |
| Hydrochloric Acid SCHEMBL17376453 | 0.83 | SLC6A2 (0.39) | SLC6A2SLC6A4SLC6A3KCNH2MLNR | |
| Fluoride SCHEMBL28166838 | 0.80 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2MLNR | |
| SCHEMBL11572913 | 0.80 | SLC6A2 (0.40) | SLC6A2SLC6A4SLC6A3KCNH2MLNR | |
| SCHEMBL12206944 | 0.80 | — | — | |
| SCHEMBL516648 | 0.80 | — | — | |
| SCHEMBL12206943 | 0.80 | — | — | |
| Hydrochloric Acid SCHEMBL28322100 | 0.80 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3KCNH2MLNR | |
| Hydrochloric Acid SCHEMBL20424103 | 0.79 | SLC6A2 (0.37) | SLC6A2SLC6A4SLC6A3KCNH2MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101870683-B | Method for preparing pinaverium bromide and intermediate compound of pinaverium bromide | SHANGHAI SINCH PHARMACEUTICALS TECH CO LTD | 2012-09-26 | — | — | CN | claimed |
| CN-101870683-A | Method for preparing pinaverium bromide and intermediate compound of pinaverium bromide | SHANGHAI SINCH PHARMACEUTICALS TECH CO LTD | 2010-10-27 | — | — | CN | claimed |
| EP-3837241-B1 | FLUORO SS-CARBOLINE COMPOUNDS FOR THE TREATMENT OF BONE HOMEOSTASIS | OSSIFI THERAPEUTICS LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260097041-A1 | FLUORO BETA-CARBOLINE COMPOUNDS | OSSIFI THERAPEUTICS LLC (US) | 2026-04-09 | — | — | US | disclosed |
| CN-120647576-A | Preparation method of morpholinyl fluoride | 陕西宝新药业有限公司 | 2025-09-16 | — | — | CN | disclosed |
| US-12324809-B2 | Fluoro beta-carboline compounds | OSSIFI THERAPEUTICS LLC (US) | 2025-06-10 | — | — | US | disclosed |
| US-20250025472-A1 | FLUORO BETA-CARBOLINE COMPOUNDS | OSSIFI THERAPEUTICS LLC | 2025-01-23 | — | — | US | disclosed |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SERVIER LAB (FR) | 2024-07-25 | — | — | US | disclosed |
| US-11903949-B2 | Fluoro beta-carboline compounds | OSSIFI THERAPEUTICS LLC (US) | 2024-02-20 | — | — | US | disclosed |
| CN-116731031-A | Down-praline derivative and application thereof | 贵州药法自然医药科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-113264978-B | Novel molecular targeting anti-tumor aza steroid derivative based on lipotoxicity and preparation method and application thereof | 重庆医科大学 | 2023-01-31 | — | — | CN | disclosed |
| US-5464831-A | Treatment of glaucoma | ALCON LABORATORIES, INC. (US) | 1995-11-07 | — | — | US | disclosed |
| US-5240923-A | Treating glaucoma | ALCON LABORATORIES, INC. (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0550924-A1 | 2-Pyrrolidinone derivatives as HIV protease inhibitors | MERCK & CO. INC. (US) | 1993-07-14 | — | — | EP | disclosed |
| US-4968819-A | CATALYTIC SELECTIVE ETHERIFICATION | ALKALOIDA VEGYESZETI GYAR (HU) | 1990-11-06 | — | — | US | disclosed |
| US-4866089-A | 7-ALKOXY-8-METHOXY-2,2-DIMETHYL-2H-CHROMENES; INSECTICIDES, NEMATOCIDES | ALKALOIDA VEGYESZETI GYAR (HU) | 1989-09-12 | — | — | US | disclosed |
| US-4808605-A | Tetrahydronaphthalene derivatives as calcium antagonists | HOFFMANN-LA ROCHE INC. (US) | 1989-02-28 | — | — | US | disclosed |
| US-4443603-A | PROTEOLYTIC ENZYME INHIBITORS | KOWA COMPANY LIMITED (JP) | 1984-04-17 | — | — | US | disclosed |
| EP-0071433-A1 | Medicine for the treatment of diabetes | KOWA COMPANY, LTD. (JP) | 1983-02-09 | — | — | EP | disclosed |
| EP-0067561-A2 | Piperazine derivatives and processes for producing them | KOWA COMPANY, LTD. (JP) | 1982-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025472-A1 | FLUORO BETA-CARBOLINE COMPOUNDS | GLS, AFF1, SLC5A1 | SLC6A2 3066/4885SLC6A4 3009/4885SLC6A3 2054/4885 |
| US-20260097041-A1 | FLUORO BETA-CARBOLINE COMPOUNDS | CTNNB1, SLC5A1, SLC5A2 | SLC6A2 101/4885SLC6A4 169/4885SLC6A3 122/4885 |
| US-20240245699-A1 | PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PDCD11, RRM2B, RRM2 | SLC6A2 4860/4885SLC6A4 4822/4885SLC6A3 4671/4885 |
| US-11903949-B2 | Fluoro beta-carboline compounds | GLS, AFF1, SLC5A1 | SLC6A2 3066/4885SLC6A4 3009/4885SLC6A3 2054/4885 |
| US-12324809-B2 | Fluoro beta-carboline compounds | GLS, AFF1, SLC5A1 | SLC6A2 3066/4885SLC6A4 3009/4885SLC6A3 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.